Mohammed, S., Fathi, Z., Mohammad, J. (2025). Leptin: Biological Functions and Metabolic Regulation in Type 2 Diabetes Mellitus. , 22(4), 215-223. doi: 10.33899/iraqij.p.2025.156767.1129
Sura khalid Mohammed; Zainab Haitham Fathi; Jehan Abdulwahab Mohammad. "Leptin: Biological Functions and Metabolic Regulation in Type 2 Diabetes Mellitus". , 22, 4, 2025, 215-223. doi: 10.33899/iraqij.p.2025.156767.1129
Mohammed, S., Fathi, Z., Mohammad, J. (2025). 'Leptin: Biological Functions and Metabolic Regulation in Type 2 Diabetes Mellitus', , 22(4), pp. 215-223. doi: 10.33899/iraqij.p.2025.156767.1129
Mohammed, S., Fathi, Z., Mohammad, J. Leptin: Biological Functions and Metabolic Regulation in Type 2 Diabetes Mellitus. , 2025; 22(4): 215-223. doi: 10.33899/iraqij.p.2025.156767.1129

Leptin: Biological Functions and Metabolic Regulation in Type 2 Diabetes Mellitus

Iraqi Journal of Pharmacy
Article 6, Volume 22, Issue 4, December 2025, Pages 215-223    PDF (801.51 K)
Document Type: Review Paper
DOI: 10.33899/iraqij.p.2025.156767.1129
Authors
Sura khalid Mohammed* 1; Zainab Haitham Fathi2; Jehan Abdulwahab Mohammad2
1Department of Pharmacy Techniques, Northen Technical University, Mosul, Iraq
2Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, University of Mosul, Mosul, Iraq
Abstract
Background: The exponential rise of Diabetes Mellitus (DM) presents significant health challenges.  Leptin is an adipokine mostly produced by white adipose tissue and is involved in regulating appetite and energy balance. Leptin modulates blood glucose levels by either central effects or peripheral effects. Objective: This review explores the biological functions and role of leptin in the pathophysiology of T2DM.Also, it aims to improve disease prediction accuracy, offer new insights into the pathophysiology, and contribute to future prevention efforts. The primary objective is to highlight leptin's biological role in T2DM.Method: The authors collected data from PubMed, Google Scholar, Research Gate, Science Direct, Elsevier, and others. The objective was to collect as much information as possible from articles using the keywords leptin and T2DM.  Conclusion: This review explores the role of leptin in T2DM, highlighting the need for multifaceted management due to its increasing prevalence and public health implications. Leptin is a potentially viable therapeutic target for T2DM.
Keywords
Type 2 diabetes; Obesity; Leptin; Insulin resistance
References
  1. Arroyave F, Montaño D, Lizcano F. Diabetes mellitus is a chronic disease that can benefit from therapy with induced pluripotent stem cells. International Journal of Molecular Sciences. 2020;21(22):8685.
  2. Roystonn K, AshaRani P, Siva Kumar FD, Wang P, Abdin E, Sum CF, et al. Factor structure of the diabetes knowledge questionnaire and the assessment of the knowledge of risk factors, causes, complications, and management of diabetes mellitus: A national population-based study in Singapore. Plos one. 2022;17(8):e0272745.
  3. Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovascular Diabetology. 2021;20:1-13.
  4. Petersmann A, Nauck M, Müller-Wieland D, Kerner W, Müller UA, Landgraf R, et al. Definition, classification and diagnosis of diabetes mellitus. Experimental and clinical endocrinology & diabetes. 2018;126(07):406-10.
  5. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological reviews. 2018.
  6. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences. 2020;21(17):6275.
  7. Leslie RD, Vartak T. Allostasis and the origins of adult-onset diabetes. Diabetologia. 2020;63(2):261-5.
  8. Scherer PE, Hill JA. Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. Circ Res. 2016;118(11):1703-5.
  9. Choudhury AA, Rajeswari VD. Gestational diabetes mellitus-A metabolic and reproductive disorder. Biomedicine & Pharmacotherapy. 2021;143:112183.
  10. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in endocrinology. 2023;14:1161521.
  11. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. The Journal of Clinical Endocrinology & Metabolism. 1999;84(4):1165-71.
  12. Wende AR, Symons JD, Abel ED. Mechanisms of lipotoxicity in the cardiovascular system. Current hypertension reports. 2012;14:517-31.
  13. Randle P, Garland P, Hales C, Newsholme E. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. The Lancet. 1963;281(7285):785-9.
  14. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, et al. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 2004;287(3):E537-E46.
  15. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1–associated phosphatidylinositol 3-kinase activity. The Journal of clinical investigation. 1999;103(2):253-9.
  16. Karnieli E, Armoni M. Regulation of glucose transporters in diabetes. Hormone Research in Paediatrics. 1990;33(2-4):99-104.
  17. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo R. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study A. Gastaldelli et al.: Beta-cell dysfunction and glucose intolerance. Diabetologia. 2004;47(1).
  18. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in endocrinology. 2023;14:1149239.
  19. Mir MM, Mir R, Alghamdi MAA, Wani JI, Sabah ZU, Jeelani M, et al. Differential association of selected adipocytokines, adiponectin, leptin, resistin, visfatin and chemerin, with the pathogenesis and progression of type 2 diabetes mellitus (T2DM) in the asir region of Saudi Arabia: A case control study. Journal of Personalized Medicine. 2022;12(5):735.
  20. Himms-Hagen J. Physiological roles of the leptin endocrine system: differences between mice and humans. Critical reviews in clinical laboratory sciences. 1999;36(6):575-655.
  21. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Hormone molecular biology and clinical investigation. 2014;18(1):37-45.
  22. Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: underlying mechanisms and diagnosis. Diabetes, metabolic syndrome and obesity: targets and therapy. 2019:191-8.
  23. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal transduction and targeted therapy. 2022;7(1):216.
  24. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, König W. Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle‐aged men and women: results from the MONICA/KORA Augsburg Study 1984–2002. Diabetic medicine. 2010;27(9):1004-11.
  25. Paz-Filho G, Mastronardi C, Wong M-L, Licinio J. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian journal of endocrinology and metabolism. 2012;16(Suppl 3):S549-S55.
  26. Staiger H, Kausch C, Guirguis A, Weisser M, Maerker E, Stumvoll M, et al. Induction of adiponectin gene expression in human myotubes by an adiponectin-containing HEK293 cell culture supernatant. Diabetologia. 2003;46:956-60.
  27. Delaigle AlM, Jonas J-C, Bauche IB, Cornu O, Brichard SM. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology. 2004;145(12):5589-97.
  28. Greco M, De Santo M, Comandè A, Belsito EL, Andò S, Liguori A, et Leptin-activity modulators and their potential pharmaceutical applications. Biomolecules. 2021;11(7):1045.
  29. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine. 1996;334(5):292-5.
  30. Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019;20(5).
  31. Pereira S, Cline DL, Glavas MM, Covey SD, Kieffer TJ. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocrine reviews. 2021;42(1):1-28.
  32. Friedman JM. Leptin at 14 y of age: an ongoing story. The American journal of clinical nutrition. 2009;89(3):973S-9S.
  33. Flier JS, Maratos-Flier E. Lasker lauds leptin. Cell Metabolism. 2010;12(4):317-20.
  34. Berglund ED, Vianna CR, Donato J, Kim MH, Chuang J-C, Lee CE, et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. The Journal of clinical investigation. 2012;122(3):1000-9.
  35. Lee G-H, Proenca R, Montez J, Carroll K, Darvishzadeh J, Lee J, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature. 1996;379(6566):632-5.
  36. Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic β-cells. Diabetes. 1997;46(6):1087-93.
  37. Anderwald C, Müller Gn, Koca G, Fürnsinn C, Waldhäusl W, Roden M. Short-term leptin-dependent inhibition of hepatic gluconeogenesis is mediated by insulin receptor substrate-2. Molecular Endocrinology. 2002;16(7):1612-28.
  38. Huang W, Dedousis N, Bhatt BA, O'Doherty RM. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. Journal of Biological Chemistry. 2004;279(21):21695-700.
  39. Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin Frontiers in neuroendocrinology. 2003;24(4):225-53.
  40. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity reviews. 2007;8(1):21-34.
  41. Meister B. Control of food intake via leptin receptors in the hypothalamus. 2000.
  42. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. The journal of clinical investigation. 1997;99(1):14-8.
  43. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochemical Journal. 2006;393(1):7-20.
  44. Torres N, Vargas-Castillo AE, Tovar AR. Adipose Tissue: White Adipose Tissue Structure and Function. In: Caballero B, Finglas PM, Toldrá F, editors. Encyclopedia of Food and Health. Oxford: Academic Press; 2016. p. 35-42.
  45. Broberger C, Johansen J, Johansson C, Schalling M, Hökfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proceedings of the National Academy of Sciences. 1998;95(25):15043-8.
  46. Kohno D, Yada T. Arcuate NPY neurons sense and integrate peripheral metabolic signals to control feeding. Neuropeptides. 2012;46(6):315-9.
  47. Leibowitz SF, Wortley KE. Hypothalamic control of energy balance: different peptides, different functions. Peptides. 2004;25(3):473-504.
  48. Speakman JR. Obesity: the integrated roles of environment and genetics. The Journal of nutrition. 2004;134(8):2090S-105S.
  49. Laque A, Zhang Y, Gettys S, Nguyen T-A, Bui K, Morrison CD, et al. Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide galanin and mediate anorexigenic leptin action. American Journal of Physiology-Endocrinology and Metabolism. 2013;304(9):E999-E1011.
  50. KALLIO J, PESONEN U, KAIPIO K, KARVONEN MK, JAAKKOLA U, HEINONEN OJ, et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans1. The FASEB Journal. 2001;15(7):1242-4.
  51. Huvenne H, Dubern B, Cl, ment K, Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obesity facts. 2016;9:158-73.
  52. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999;22(2):221-32.
  53. Elias CF, Aschkenasi C, Lee C, Kelly J, Ahima RS, Bjorbæk C, et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron. 1999;23(4):775-86.
  54. Fekete C, Légrádi G, Mihály E, Huang Q-H, Tatro JB, Rand WM, et al. α-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. Journal of Neuroscience. 2000;20(4):1550-8.
  55. Farr SA, Banks WA, Morley JE. Effects of leptin on memory processing. Peptides. 2006;27(6):1420-5.
  56. Piattini F, Le Foll C, Kisielow J, Rosenwald E, Nielsen P, Lutz T, et al. A spontaneous leptin receptor point mutation causes obesity and differentially affects leptin signaling in hypothalamic nuclei resulting in metabolic dysfunctions distinct from db/db mice. Molecular metabolism. 2019;25:131-41.
  57. Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. Circulation research. 2021;128(1):136-49.
  58. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol. 2010;31(3):377-93.
  59. Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients. 2019;11(11):2704.
  60. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biological psychiatry. 1998;44(9):851-64.
  61. Duffy ME, Stewart-Knox BJ, McConville C, Bradbury I, O’Connor J, Helander A, et al. The relationship between whole-blood serotonin and subjective mood in apparently healthy postmenopausal women. Biological Psychology. 2006;73(2):165-8.
  62. Stunes A, Reseland JE, Hauso Ø, Kidd M, Tømmerås K, Waldum H, et al. Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. Diabetes, Obesity and Metabolism. 2011;13(6):551-8.
  63. Aronne L, Thornton‐Jones Z. New targets for obesity pharmacotherapy. Clinical Pharmacology & Therapeutics. 2007;81(5):748-52.
  64. Park H-J, Lee S-E, Oh J-H, Seo K-W, Song K-H. Leptin, adiponectin and serotonin levels in lean and obese dogs. BMC veterinary research. 2014;10:1-8.
  65. Pérez-Pérez A, Vilariño-García T, Fernández-Riejos P, Martín-González J, Segura-Egea JJ, Sánchez-Margalet V. Role of leptin as a link between metabolism and the immune system. Cytokine & growth factor reviews. 2017;35:71-84.
  66. Singh H, Almabhouh FA, Alshaikhli HSI, Hassan MJM, Daud S, Othman R, et al. Leptin in reproduction and hypertension in pregnancy. Reproduction, Fertility and Development. 2024;36(12).
  67. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305-17.
  68. Flier JS. Starvation in the midst of plenty: reflections on the history and biology of insulin and leptin. Endocrine reviews. 2019;40(1):1-16.
  69. Martínez-Sánchez N. There and back again: leptin actions in white adipose tissue. International journal of molecular sciences. 2020;21(17):6039.
  70. Zhao S, Kusminski CM, Elmquist JK, Scherer PE. Leptin: less is more. Diabetes. 2020;69(5):823-9.
  71. Stefanović A, Kotur-Stevuljević J, Spasić S, Bogavac-Stanojević N, Bujisić N. The influence of obesity on the oxidative stress status and the concentration of leptin in type 2 diabetes mellitus patients. Diabetes Res Clin Pract. 2008;79(1):156-63.
  72. Manglani K, Anika NN, Patel D, Jhaveri S, Avanthika C, Sudan S, et al. Correlation of Leptin in Patients With Type 2 Diabetes Mellitus. Cureus. 2024;16(4).
  73. Abdella NA, Mojiminiyi OA, Moussa MA, Zaki M, Al Mohammedi H, Al Ozairi ES, et al. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabet Med. 2005;22(3):278-85.
  74. Kumar R, Mal K, Razaq MK, Magsi M, Memon MK, Memon S, et al. Association of leptin with obesity and insulin resistance. Cureus. 2020;12(12).
  75. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984-2002. Diabet Med. 2010;27(9):1004-11.
  76. Simha V. Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy. Expert review of endocrinology & metabolism. 2014;9(3):205-12.
  77. Frank-Podlech S, von Schnurbein J, Veit R, Heni M, Machann J, Heinze JM, et al. Leptin replacement reestablishes brain insulin action in the hypothalamus in congenital leptin deficiency. Diabetes Care. 2018;41(4):907-10.
  78. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine. 2002;346(8):570-8.
  79. Kruger AJ, Yang C, Lipson KL, Pino SC, Leif JH, Hogan CM, et al. Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats. Autoimmunity. 2011;44(2):137-48.
  80. Vasandani C, Clark GO, Adams-Huet B, Quittner C, Garg A. Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: a pilot study. Diabetes care. 2017;40(5):694-7.
  81. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nature reviews Drug discovery. 2012;11(9):692-708.
  82. Moon H-S, Matarese G, Brennan AM, Chamberland JP, Liu X, Fiorenza CG, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes. 2011;60(6):1647-56.
  83. Liu J, Yang X, Yu S, Zheng R. The leptin resistance. Neural Regulation of Metabolism. 2018:145-63.
  84. Crujeiras AB, Carreira MC, Cabia B, Andrade S, Amil M, Casanueva FF. Leptin resistance in obesity: an epigenetic landscape. Life sciences. 2015;140:57-63.
  85. Müller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, Grant E, et al. Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21. Journal of Peptide Science. 2012;18(6):383-93.
  86. Starling S. New therapeutic promise for leptin. Nature Reviews ndocrinology. 2019;15(11):625.
Statistics
Article View: 396
PDF Download: 181


Journal Management System. Powered by iJournalPro.com